Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 27
Filtrar
1.
Acta Physiol (Oxf) ; 240(8): e14188, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-38874396

RESUMEN

Chemotherapy is a common and effective treatment for cancer, but these drugs are also associated with significant side effects affecting patients' well-being. One such debilitating side effect is mucositis, characterized by inflammation, ulcerations, and altered physiological functions of the gastrointestinal (GI) tract's mucosal lining. Understanding the mechanisms of chemotherapy-induced intestinal mucositis (CIM) is crucial for developing effective preventive measures and supportive care. Chemotherapeutics not only target cancer cells but also rapidly dividing cells in the GI tract. These drugs disrupt endoplasmic reticulum (ER) homeostasis, leading to ER-stress and activation of the unfolded protein response (UPR) in various intestinal epithelial cell types. The UPR triggers signaling pathways that exacerbate tissue inflammation and damage, influence the differentiation and fate of intestinal epithelial cells, and compromise the integrity of the intestinal mucosal barrier. These factors contribute significantly to mucositis development and progression. In this review, we aim to give an in-depth overview of the role of ER-stress in mucositis and its impact on GI function. This will provide valuable insights into the underlying mechanisms and highlighting potential therapeutic interventions that could improve treatment-outcomes and the quality of life of cancer patients.


Asunto(s)
Antineoplásicos , Estrés del Retículo Endoplásmico , Mucositis , Humanos , Estrés del Retículo Endoplásmico/efectos de los fármacos , Mucositis/inducido químicamente , Mucositis/metabolismo , Antineoplásicos/efectos adversos , Animales , Respuesta de Proteína Desplegada/efectos de los fármacos , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología
2.
Front Public Health ; 11: 1233264, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37711235

RESUMEN

Background: This review wants to highlight the importance of computer programs used to control the steps in the management of dangerous drugs. It must be taken into account that there are phases in the process of handling dangerous medicines in pharmacy services that pose a risk to the healthcare personnel who handle them. Objective: To review the scientific literature to determine what computer programs have been used in the field of hospital pharmacy for the management of dangerous drugs (HDs). Methods: The following electronic databases were searched from inception to July 30, 2021: MEDLINE (via PubMed), Embase, Cochrane Library, Scopus, Web of Science, Latin American and Caribbean Literature in Health Sciences (LILACS) and Medicine in Spanish (MEDES). The following terms were used in the search strategy: "Antineoplastic Agents," "Cytostatic Agents," "Hazardous Substances," "Medical Informatics Applications," "Mobile Applications," "Software," "Software Design," and "Pharmacy Service, Hospital." Results: A total of 104 studies were retrieved form the databases, and 18 additional studies were obtained by manually searching the reference lists of the included studies and by consulting experts. Once the inclusion and exclusion criteria were applied, 26 studies were ultimately included in this review. Most of the applications described in the included studies were used for the management of antineoplastic drugs. The most commonly controlled stage was electronic prescription; 18 studies and 7 interventions carried out in the preparation stage focused on evaluating the accuracy of chemotherapy preparations. Conclusion: Antineoplastic electronic prescription software was the most widely implemented software at the hospital level. No software was found to control the entire HD process. Only one of the selected studies measured safety events in workers who handle HDs. Moreover, health personnel were found to be satisfied with the implementation of this type of technology for daily work with these medications. All studies reviewed herein considered patient safety as their final objective. However, none of the studies evaluated the risk of HD exposure among workers.


Asunto(s)
Aplicaciones Móviles , Servicio de Farmacia en Hospital , Humanos , Región del Caribe , Bases de Datos Factuales , Etnicidad
3.
Cells ; 12(4)2023 02 12.
Artículo en Inglés | MEDLINE | ID: mdl-36831260

RESUMEN

Flavonoids exert many beneficial properties, such as anticancer activity. They were found to have chemopreventive effects hindering carcinogenesis, and also being able to affect processes important for cancer cell pathophysiology inhibiting its growth or promoting cell death. There are also reports on the chemosensitizing properties of flavonoids, which indicate that they could be used as a support of anticancer therapy. It gives promise for a novel therapeutic approach in tumors characterized by ineffective treatment, such as high-grade gliomas. The research was conducted on the in vitro culture of human SW1783 anaplastic astrocytoma cells incubated with neobavaisoflavone (NEO), doxorubicin, etoposide, and their combinations with NEO. The analyses involved the WST-1 cell viability assay and image cytometry techniques including cell count assay, Annexin V assay, the evaluation of mitochondrial membrane potential, and the cell-cycle phase distribution. We found that NEO affects the activity of doxorubicin and etoposide by reducing the viability of SW1783 cells. The combination of NEO and etoposide caused an increase in the apoptotic and low mitochondrial membrane potential subpopulations of SW1783 cells. Changes in the cell cycle were observed in all combined treatments. These findings indicate a potential chemosensitizing effect exerted by NEO.


Asunto(s)
Astrocitoma , Isoflavonas , Humanos , Etopósido/farmacología , Doxorrubicina/farmacología , Astrocitoma/patología , Isoflavonas/uso terapéutico , Línea Celular Tumoral
4.
Artículo en Inglés | MEDLINE | ID: mdl-36833599

RESUMEN

Recently, the quest for novel glaucoma surgical techniques and devices has been underway. Trabeculectomy remains the gold standard, but it requires the implantation of glaucoma drainage devices and frequent follow-ups, and it also carries a high risk of serious complications. The need for less invasive and safer procedures has led to the development of minimally invasive glaucoma surgery (MIGS), particularly for patients with mild-to-moderate disease. Among them, minimally invasive bleb surgery seems to be effective in classical glaucoma surgery, while maintaining MIGS benefits. The relatively new PreserFlo® MicroShunt (Santen, Osaka, Japan) is registered in Europe. It was released in 2019 for the treatment of patients with early-to-advanced open-angle glaucoma, where intraocular pressure (IOP) remains uncontrolled while on maximum tolerated medication and/or where glaucoma progression warrants surgery. This review focuses on the place of the PreserFlo MicroShunt, characterized by ab externo implantation, among MIGS procedures, discussing its advantages and disadvantages. The mechanisms of action, technical aspects, efficacy, and safety issues are summarized. The surgical technique, its efficacy, and safety profile are described, and directions for future studies are indicated. The PreserFlo MicroShunt ensures a high safety profile, minimal anatomical disruption, meaningful IOP-lowering effect, and ease of use for patients and physicians.


Asunto(s)
Implantes de Drenaje de Glaucoma , Glaucoma de Ángulo Abierto , Glaucoma , Humanos , Glaucoma de Ángulo Abierto/etiología , Glaucoma de Ángulo Abierto/cirugía , Presión Intraocular , Implantes de Drenaje de Glaucoma/efectos adversos , Tonometría Ocular
5.
Orv Hetil ; 163(41): 1614-1628, 2022 Oct 09.
Artículo en Húngaro | MEDLINE | ID: mdl-36209421

RESUMEN

The epidemiological indicators of malignant diseases and diabetes are changing similarly, as lately both have been dynamically increasing worldwide. They occur usually in the same patient synchronously or metachronously, because of their common metabolic and molecular background. Consequently, in more and more cases they require common treatment. That has led to a new science, called oncodiabetology, the main purpose of which is to optimize the combination of antineoplastic and antidiabetic therapies. Regarding the antineoplastic agents, their complex influence on metabolism has to be considered, especially diabetogenic side effects inducing insulin-resistance and decreasing insulin production. According to antidiabetic agents' role in preventing tumors, diminishing toxicity of cytostatic drugs, and promoting the breakthrough of chemoresistance should be considered. In this study, we investigate the contexts of antineoplastic agents' efficiency and the glucometabolism of the organization, the characteristics of oncotherapy in patients suffering from malignant disease and diabetes, and review those cytostatic agents, having massive diabetogenic adverse effects. We describe the properties and subtypes of secondary diabetes, thoroughly discuss the specific characteristics of hyperglycaemia and diabetes caused by malignant diseases and antineoplastic treatments, especially pancreatic diabetes. In the end, we attempt to determine the proper place and role of oncodiabetology in the treatment of patients suffering from malignancies. During our investigation, we assessed the effects on glucometabolism of the recently used classic cytostatics, molecularly targeted therapies and different endocrine manipulations treating malignancies. We reviewed the schedules and scientific background of almost 300 medicines for this aim. We established that every third antineoplastic agent influenced glucometabolism adversely. We report our further observations in our next reviews.


Asunto(s)
Antineoplásicos , Citostáticos , Diabetes Mellitus , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Neoplasias , Antineoplásicos/efectos adversos , Diabetes Mellitus/tratamiento farmacológico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos/tratamiento farmacológico , Humanos , Hipoglucemiantes/uso terapéutico , Insulina , Neoplasias/tratamiento farmacológico
6.
J Pers Med ; 11(11)2021 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-34834504

RESUMEN

Sarcomas are characterized by a high metastatic potential and aggressive growth. Despite surgery, chemotherapy plays an important role in the treatment of these tumors. Optimal anti-cancer therapy with maximized local efficacy and minimized systemic side effects has been the object of many studies for a long time. To improve the local efficacy of anti-tumor therapy, isolated limb perfusion with high-dose cytostatic agents has been introduced in surgical oncology. In order to control the local distribution of substances, radiolabeled cytostatic drugs or perfusion solutions have been applied but often require the presence of specialized personnel and result in a certain exposure to radiation. In this study, we present a novel strategy using indocyanine green to track tumor perfusion with high-dose cytostatic therapy. In a rat cadaver model, the femoral vessels were cannulated and connected to a peristaltic pump to provide circulation within the selected limb. The perfusion solution contained indocyanine green and high-dose doxorubicin. An infrared camera enabled the visualization of indocyanine green during limb perfusion, and subsequent leakage control was successfully performed. Histologic analysis of sections derived proximally from the injection site excluded systemic drug dispersion. In this study, the application of indocyanine green was proven to be a safe and cost- and time-efficient method for precise leakage control in isolated limb perfusion with a high-dose cytostatic agent.

7.
Farm. hosp ; 45(5): 282-286, septiembre-octubre 2021. tab
Artículo en Español | IBECS | ID: ibc-218721

RESUMEN

Objetivo: Describir el protocolo del estudio para la instauración del control del proceso de los medicamentos peligrosos que asegure la calidady su trazabilidad, mediante el análisis de riesgos, desarrollando e implantando una herramienta informatizada que, gracias a la utilización de técnicas de big data, permita conocer y auditar el conjunto del sistema de formacontinua y dinámica.Método: Mediante los procesos de notación gráfica normalizada Business Process Model Notation se desarrollarán los flujogramas específicosque permitan conocer las etapas del proceso de los medicamentos peligrosos que determinen la trazabilidad total del sistema. Cada una de lasetapas será recogida en los cuadros de gestión, donde a través de laprobabilidad del suceso y su gravedad se calculará el índice de criticidadde cada punto de control que se determine, y se establecerán las medidasde control. A partir de los cuadros de gestión se desarrollará el soportetecnológico para la captura de todos los datos que sean pertinentes al modelo. Para asegurar el control de la calidad del proceso se optará poragentes software cliente, que permitan en fases posteriores aplicar herramientas eficientes en el procesamiento de datos de modo automático. Apartir de aproximaciones metodológicas del big data, y en particular delámbito de machine learning, se desarrollarán algoritmos sobre el repositorio de datos generado para poder obtener patrones que permitan mejorarlos protocolos de aplicación. Por último, para asegurar el funcionamientodel proceso se realizará la verificación clínico-farmacéutica y la revisióncompleta, técnico-documental, de los sistemas de control y registro. (AU)


Objective: This article describes a study protocol for the implementation of quality and traceability control in the hazardous medication circuitthrough an analysis of risks and the development and introduction of a BigData-based software application aimed at performing a continuous anddynamic audit of the whole system.Method: A standardized graphical modeling tool called Business Process Model Notation will be used to generate a detailed description ofeach of the stages in the hazardous medication circuit with a view to ensuring full traceability of the system. The information on each stage will becollected in a flowchart, which will be used —together with each event’slikelihood of occurrence and severity— as a basis to calculate the criticality index of the different control points established and to determine anycontrol measures that may be required. The flowcharts will also be usedto develop the technological support needed to capture all such data asmay be relevant to the model. Proper quality control of the process will be ensured by client software agents intended to allow automatic application of efficient data processing tools at the different phases. In addition,Big Data methodologies, in particular machine learning, will be used todevelop algorithms based on the repository of generated data to comeup with patterns capable of improving the protocols to be applied. Lastly,proper operation of the process will be ensured by means of clinicalpharmaceutical verification and a full technical-documentary review ofcontrol and registration systems. (AU)


Asunto(s)
Humanos , Sustancias Peligrosas , Antineoplásicos , Citostáticos , Salud Laboral , Control de Calidad , Gestión de la Información , Medición de Riesgo
8.
Enferm. clín. (Ed. impr.) ; 31(4): 247-253, Jul-Ago. 2021. ilus
Artículo en Español | IBECS | ID: ibc-220644

RESUMEN

Objetivo: Analizar el riesgo genotóxico de los fármacos citostáticos en personal sanitario tras su exposición ocupacional. Método: Revisión narrativa mediante búsqueda bibliográfica en bases de datos Pubmed, Lilacs, The Cochrane Library y Scopus, con lenguaje libre y controlado (términos MeSH) utilizando los operadores booleanos AND y OR. La búsqueda se limitó a artículos publicados entre 2005-2016. Resultados. Se analizaron 11 artículos seleccionados para esta revisión bibliográfica en función de su relevancia, de los cuales 9 mostraban daño en el material genético (ADN) del personal sanitario expuesto a citostáticos. Además, cabe señalar que las actuales prácticas de seguridad no eliminan por completo las posibilidades de exposición, por lo que es necesaria la creación de nuevos estudios clínicos. Conclusiones: La manipulación de citostáticos puede causar un riesgo genotóxico al personal sanitario que se encuentra expuesto a estas sustancias. Dicho riesgo puede producir modificaciones en el ADN del organismo de estos trabajadores. No existen datos suficientes para demostrar la relación causa-efecto entre el riesgo genotóxico y el efecto adverso en el individuo. La educación para la salud será el principal medio para la concienciación y prevención del personal en riesgo.(AU)


Objective. To analyse the genotoxic risk of cytostatic drugs in health professionals after occupational exposure. Method: The literature was searched using the databases PubMed, Lilacs, The Cochrane Library and Scopus with free and controlled language (MeSH terms) using Boolean operators AND and OR. The research was limited to articles published between 2005-2016. Results: 11 articles were selected depending on their relevancy to this review's aim. Nine of the 11 articles proved the existence of damage to genetic material (DNA) of health workers, who were exposed to cytostatics. Furthermore, current security practices do not fully eliminate the chance of exposure. Therefore, new clinical trials are required. Conclusions: Handling cytostatic drugs can cause a genotoxic risk to health workers who are exposed to these substances. This exposure may cause damage to the workers’ DNA. There are not enough data to prove a cause-effect relationship between the genotoxic risk and adverse reactions in individuals. Health education will be the main way to raise awareness of and prevent this problem.(AU)


Asunto(s)
Humanos , Personal de Salud , Exposición Profesional , Citostáticos , Daño del ADN , Genotoxicidad
9.
Enferm Clin (Engl Ed) ; 31(4): 247-253, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34243912

RESUMEN

OBJECTIVE: To analyse the genotoxic risk of cytostatic drugs in health professionals after occupational exposure. METHOD: Literature was searched for the databases PubMed, Lilacs, The Cochrane Library and Scopus with free and controlled language (MeSH terms) using boolean operators AND and OR. The research was limited to articles published between 2005-2016. RESULTS: 11 articles were selected depending on their relevancy to this review's aim. Nine of the 11 articles proved the existence of damage to genetic material (DNA) of health workers, who were exposed to cytostatics. Furthermore, current security practices do not eliminate the chance of exposure completely. Therefore, the creation of new clinical trials is required. CONCLUSIONS: Handling cytostatic drugs can cause a genotoxic risk to health workers who are exposed to these substances. This exposure may cause damage on the workers' DNA. There are not enough data to prove a cause-effect relationship between the genotoxic risk and adverse reactions on individuals. Health education will be the main way to raise the awareness and prevention this problem.


Asunto(s)
Citostáticos , Exposición Profesional , Citostáticos/efectos adversos , Daño del ADN , Personal de Salud , Fuerza Laboral en Salud , Humanos , Exposición Profesional/efectos adversos
10.
BMC Complement Med Ther ; 21(1): 186, 2021 Jul 02.
Artículo en Inglés | MEDLINE | ID: mdl-34215240

RESUMEN

BACKGROUND: Melanoma and breast cancers are two common cancers worldwide. Due to the side effects of chemotherapy drugs and the occurring resistance against them, the development of green drugs has been received more attention. METHODS: The anticancer effects of three essential oils from the Citrus family and their identified major constituents (limonene) were first investigated against melanoma and breast cancer cell lines (A-375 and MDA-MB-468). By preparing chitosan nanoparticles containing them, an attempt was then made to improve their effectiveness. RESULTS: Chitosan nanoparticles containing Citrus sinensis and Citrus limon essential oils with IC50s of 0.03 and 0.124 µg/mL on A-375 cells, and 23.65 and 40.32 µg/mL on MDA-MB-468 showed distinct anticancer efficacies. CONCLUSION: The prepared formulations could thus be considered as green anticancer agents in complementary medicine and therapies.


Asunto(s)
Quitosano/química , Citrus , Limoneno/farmacología , Fitoterapia , Antineoplásicos Fitogénicos/farmacología , Neoplasias de la Mama/tratamiento farmacológico , Línea Celular Tumoral , Sistemas de Liberación de Medicamentos , Femenino , Humanos , Melanoma/tratamiento farmacológico , Nanopartículas/química
11.
Cell Stress ; 4(10): 248-251, 2020 Aug 06.
Artículo en Inglés | MEDLINE | ID: mdl-33024933

RESUMEN

The widespread application of immune-checkpoint blockade (ICB) has resulted in unprecedented response rates in patients with immunogenic cancers, such as melanoma and lung cancer. However, sub-groups of patients with these indications do not respond to ICB, and the same applies to patients with other cancer types. Mechanisms of resistance to ICB include low tumor immunogenicity associated with low T cell infiltration ('cold' tumors), suppression of anti-tumor immunity by immunosuppressive cells in the tumor microenvironment (TME), lack of antigen-presentation and immune escape (e.g. by downregulation of MHC-I on tumor cells) as well as oncologic pathways that suppress immune responses. Combination strategies, involving cytostatic drugs, harbor the potential to overcome refractoriness to immunotherapy. However, suppression of immune cell function by cytostatic drugs may limit the efficacy. In our study, we show that combination treatment of targeted inhibition of mitogen-activated protein kinase (MAPK) kinase (MEK) and agonist immunostimulatory anti-CD40 antibody (Ab) is particularly suitable in counteracting aforementioned ICB resistance mechanisms (Fig. 1).

12.
Artículo en Inglés, Español | MEDLINE | ID: mdl-31506228

RESUMEN

OBJECTIVE: To analyse the genotoxic risk of cytostatic drugs in health professionals after occupational exposure. METHOD: The literature was searched using the databases PubMed, Lilacs, The Cochrane Library and Scopus with free and controlled language (MeSH terms) using Boolean operators AND and OR. The research was limited to articles published between 2005-2016. RESULTS: 11 articles were selected depending on their relevancy to this review's aim. Nine of the 11 articles proved the existence of damage to genetic material (DNA) of health workers, who were exposed to cytostatics. Furthermore, current security practices do not fully eliminate the chance of exposure. Therefore, new clinical trials are required. CONCLUSIONS: Handling cytostatic drugs can cause a genotoxic risk to health workers who are exposed to these substances. This exposure may cause damage to the workers' DNA. There are not enough data to prove a cause-effect relationship between the genotoxic risk and adverse reactions in individuals. Health education will be the main way to raise awareness of and prevent this problem.

13.
J Oncol Pharm Pract ; 25(5): 1204-1216, 2019 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-30895861

RESUMEN

This article compares gravimetry vs. high-performance liquid chromatography (HPLC) as quality control (QC) methods for paclitaxel, docetaxel and oxaliplatin preparations. We aimed at assessing the preparation method reliability in our hospital, evaluating compounding accuracy and estimating the influence of personnel training and standardized homogenization on compounding accuracy. Agreement, correlation, concordance, accuracy and precision between methods were evaluated for each drug. Conforming preparation percentages (CPs) at different tolerance limits (TLs) and compounding accuracy were calculated for each method and drug. Compounding accuracy was compared before and after personnel training and standardized homogenization implantation. SPSS v 20.0 and Ene v 2.0 were used. A total of 222 samples (58 docetaxel, 95 paclitaxel and 69 oxaliplatin) were analyzed. Gravimetry and HPLC are comparable methods. Overall CP was 81% for gravimetry at 10% TL and 85% for HPLC at 15% TL. Compounding accuracy is shown to be good for all methods and drugs. Homogenization optimization and personnel training make measurements more accurate for docetaxel and paclitaxel HPLC, but seem to worsen accuracy for docetaxel gravimetry. Gravimetry has shown to be a good alternative to HPLC for routine QC. Coupling with electronic methods should be considered in the future.


Asunto(s)
Antineoplásicos/análisis , Cromatografía Líquida de Alta Presión/métodos , Control de Calidad , Antineoplásicos/normas , Docetaxel/análisis , Humanos , Paclitaxel/análisis , Reproducibilidad de los Resultados
14.
Clin Transl Oncol ; 21(10): 1357-1363, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-30788835

RESUMEN

PURPOSE: Our main aim is to analyze the survival results in women operated on for advanced ovarian cancer with two different HIPEC regimens (cisplatin plus doxorubicin versus paclitaxel). PATIENTS AND METHODS: A prospective cohort of patients with stage IIIC or IV epithelial ovarian cancer operated on with cytoreductive surgery and HIPEC, from October-2008 to February-2016, was retrospectively analyzed. The two drugs used, cisplatin/doxorubicin (Group A) and paclitaxel (Group B), were compared. RESULTS: Forty-one patients were treated with cytoreductive surgery and HIPEC; 19 patients (46%) were in Group A and 22 (54%) were in Group B. The extent of peritoneal disease was comparable between groups (Peritoneal Cancer Index of 10 in Group A versus PCI of 12.5 in Group B). There were no differences in morbidity between groups, with a severe morbidity (Dindo-Clavien III or IV) of 36.8% versus 27.3%, respectively. There was no postoperative mortality. Median follow-up was 39 months. Median overall survival was 79 months. Overall survival at 3 years in Group A was 66% versus 82.9% in Group B (p = 0.248). Incomplete cytoreduction (macroscopic residual tumour after surgery) was identified as the only independent factor that influenced overall survival (HR 12.30, 95% CI 1.28-118.33, p = 0.03). The cytostatic used in HIPEC had no influence in overall survival. CONCLUSION: The cytostatic used in HIPEC did not have a negative effect in the prognosis of patients with advanced ovarian cancer.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma Epitelial de Ovario/terapia , Hipertermia Inducida , Neoplasias Ováricas/terapia , Neoplasias Peritoneales/terapia , Adulto , Anciano , Carcinoma Epitelial de Ovario/mortalidad , Carcinoma Epitelial de Ovario/patología , Cisplatino/administración & dosificación , Terapia Combinada/efectos adversos , Terapia Combinada/métodos , Procedimientos Quirúrgicos de Citorreducción/efectos adversos , Procedimientos Quirúrgicos de Citorreducción/estadística & datos numéricos , Doxorrubicina/administración & dosificación , Femenino , Humanos , Hipertermia Inducida/efectos adversos , Hipertermia Inducida/estadística & datos numéricos , Persona de Mediana Edad , Neoplasia Residual , Neoplasias Ováricas/mortalidad , Neoplasias Ováricas/patología , Paclitaxel/administración & dosificación , Neoplasias Peritoneales/mortalidad , Neoplasias Peritoneales/patología , Estudios Prospectivos , Estudios Retrospectivos
15.
Protein Pept Lett ; 25(7): 626-632, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29921196

RESUMEN

BACKGROUND: Cancer is considered one of the most predominant causes of morbidity and mortality all over the world and colorectal cancer is the most common fatal cancers, triggering the second cancer related death. Despite progress in understanding carcinogenesis and development in chemotherapeutics, there is an essential need to search for improved treatment. More than the half a century, cytotoxic and cytostatic agents have been examined as a potential treatment of cancer, among these agents; remarkable progresses have been reported by the use of the snake venom. Snake venoms are secreting materials of lethal snakes are store in venomous glands. Venoms are composite combinations of various protein, peptides, enzymes, toxins and non proteinaceous secretions. CONCLUSION: Snake venom possesses immense valuable mixtures of proteins and enzymes. Venoms have potential to combat with the cancerous cells and produce positive effect. Besides the toxicological effects of venoms, several proteins of snake venom e.g. disintegrins, phospholipases A2, metalloproteinases, and L-amino acid oxidases and peptides e.g. bradykinin potentiators, natriuretic, and analgesic peptides have shown potential as pharmaceutical agents, including areas of diagnosis and cancer treatment. In this review we have discussed recent remarkable research that has involved the dynamic snake venoms compounds, having anticancer bustle especially in case of colorectal cancer.


Asunto(s)
Antineoplásicos , Neoplasias Colorrectales/tratamiento farmacológico , Citostáticos , Venenos de Serpiente , Animales , Humanos , Serpientes
16.
Chemosphere ; 190: 417-430, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29024886

RESUMEN

This study analyses the presence of 17 cytostatic agents from seven different groups, based on their different mechanisms of action, in the effluent from a medium-sized hospital located in eastern Spain. Analysis of the compounds found in the effluents studied involved solidphase extraction (SPE) coupled on-line to a high performance liquid chromatograph tandem mass spectrometer (HPLC-MS/MS). The environmental risk of the compounds studied was then assessed by calculating the hazard quotient (HQ), combining the measured environmental concentrations (MECs) with dose-response data based on the predicted no effect concentrations (PNECs). In addition, the environmental hazard associated was evaluated in accordance with their intrinsic characteristics by calculating the PBT (Persistence Bioaccumulation Toxicity) index. The results of this study showed the presence of seven of the 17 compounds analysed in a range of between 25 and 4761 ng/L. The highest concentrations corresponded to ifosfamide (58-4761 ng/L), methotrexate (394-4756 ng/L) and cyclophosphamide (46-3000 ng/L). Assessment of the environmental hazard showed that the three hormonal agents (tamoxifen and its metabolites endoxifen and hydroxytamoxifen) exhibited a maximum PBT value of 9 due to their inherent harm to the environment resulting from their characteristics of persistence, bioaccumulation and toxicity. A combined evaluation of the risk and environmental hazard showed that three of the 17 compounds studied, namely, ifosfamide, imatinib and irinotecan, all of which exhibited HQ values higher than 10 and PBT indices of 6, indicative of a particularly high potential to harm the environment, deserve special attention.


Asunto(s)
Citostáticos/análisis , Monitoreo del Ambiente/métodos , Hospitales/normas , Contaminantes Químicos del Agua/análisis , Cromatografía Líquida de Alta Presión , Humanos , Medición de Riesgo , Extracción en Fase Sólida/métodos , España , Espectrometría de Masas en Tándem
17.
Clin Transl Oncol ; 19(9): 1099-1106, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28361329

RESUMEN

PURPOSE: To evaluate the effectiveness of safeguards introduced in the process of using cytostatic agents for increasing the safety of oncology patients. METHODS: Prospective hospital study conducted in two stages, before and after the implementation of safeguards: staff training, standardized procedures, computerized prescription, pharmaceutical validation, implementation of bar codes, and a new manual on drug interactions. Medication errors (MEs) were actively recorded during the process of administering chemotherapy in the Medical Oncology Department. The study classified MEs by the stage of the medication process in which they occurred and assessed their severity. RESULTS: 500 patients, 250 before implementing safeguards and 250 afterward, were included in this study . Out of all patients included before, 43.1% had at least 1 error, compared to 27% of those included later. The number of MEs detected before and after was 144 vs. 95: 125 vs. 55 prescription errors, 2 vs. 5 validation errors, 14 vs. 4 preparation errors, 3 vs. 1 dispensation errors and 0 vs. 30 administration errors. The number of MEs that reached the patient before and after safeguard implementation was 16.7% vs. 6.3%. After the safeguards were introduced, all MEs that could have caused harm or required monitoring of some kind were prevented. CONCLUSIONS: Implementing safeguards in the hospital's cytostatic treatment cycle is useful for preventing MEs. Computerized prescription, pharmaceutical validation, and the creation/dissemination of proper work procedures are effective barriers that keep MEs from reaching the patient. Administering chemotherapy with a bar-code system facilitates detection error detection at this stage of the cycle and prevents them from reaching the patient.


Asunto(s)
Antineoplásicos/uso terapéutico , Errores de Medicación/prevención & control , Neoplasias/tratamiento farmacológico , Seguridad del Paciente/normas , Adulto , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos , España
18.
BMC Res Notes ; 10(1): 39, 2017 Jan 13.
Artículo en Inglés | MEDLINE | ID: mdl-28086959

RESUMEN

BACKGROUND: E-learning is an established concept in oncological education and training. However, there seems to be a scarcity of long-term assessments of E-learning programs in oncology vis-á-vis their structural management and didactic value. This study presents descriptive, nationwide data from 2005 to 2014. E-learning oncology programs in chemotherapy, general oncology, pain management, palliative care, psycho-social-oncology, and radiotherapy, were reviewed from our databases. Questionnaires of self-perceived didactic value of the programs were examined 2008-2014. RESULTS: The total number of trainees were 4693, allocated to 3889 individuals. The trainees included medical doctors (MDs; n = 759), registered nurses (RNs; n = 2359), radiation therapy technologists (n = 642), and, social and health care assistants (SHCAs; n = 933). The E-learning covered 29 different program classifications, comprising 731 recorded presentations, and covering 438 themes. A total of 490 programs were completed by the trainees. The European Credit Transfer and Accumulation System (ECTS; 1 ECTS point equals 0.60 US College Credit Hours) points varied across the educational programs from 0.7 to 30.0, corresponding to a duration of full-time studies ranging between 15 to 900 h (0.4-24 weeks) per program. The total number of ECTS points for the trainee cohort, was 20,000 corresponding to 530,000 full-time academic hours or 324.0 standard academic working years. The overall drop-out rate, across professions and programs, was 10.6% (499/4693). The lowest drop-out rate was seen for RNs (4.3%; P < 0.0001). Self-reported evaluation questionnaires (2008-2014) were completed by 72.1% (2642/3666) of the trainees. The programs were overall rated, on a 5-categorical scale (5 = excellent; 1 = very inferior), as excellent by 68.6% (MDs: 64.9%; RNs: 66.8%; SHCAs: 77.7%) and as good by 30.6% (MDs: 34.5%; RNs: 32.4%; SHCAs: 21.5%) of the responders. CONCLUSIONS: This descriptive study, performed in a lengthy timeframe, presents high-volume data from multi-professional, oncological E-learning programs. While the E-learning paradigm, across professions, seems to have been well received, it is imperative that prospective studies, benchmarking against traditional training methods, are carried out, examining the hypothesized didactic value of our E-programs.


Asunto(s)
Internet , Aprendizaje , Oncología Médica/educación , Enfermería Oncológica/educación , Dinamarca , Humanos
19.
J Oral Pathol Med ; 46(4): 259-266, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27598726

RESUMEN

BACKGROUND: Head and neck cancers comprise the sixth most common cancer type worldwide. One of the most remarkable malignancies of the head and neck is the cancer of the nasopharynx, with a strong metastatic tendency already in the early stage. Besides the conventional pathways of metastasis formation, the information content of exosomes produced by the cancer cells may play a key role in metastatic transformation. The aim of this study was to investigate how stressors alter the characteristic of tumor derived exosomes. METHODS: In our experimental model, we compared the quantity and content of exosomes produced by a nasopharyngeal carcinoma cell line (5-8F) under conventional (chemotherapy) and alternative (Ag-TiO2 -catalyzed reactive oxygen species generation) cytostatic treatment. After isolation, exosomes were identified by atomic force microscopy and quantified with Nanosight NS500 device. MicroRNA content of them was analyzed using SOLiD 5500xl technology. The sequences were annotated in CLC Genomics Workbench version 5.5.1. RESULTS: Beyond the classic chemotherapeutic agent (doxorubicin), Ag-TiO2 in a photo-catalytic process also showed cytostatic activity. Tumor cell damage induced by the cytostatic treatments significantly altered the number of released exosomes and led to the predominance of tumor suppressors in the exosomal miRNA profile. CONCLUSIONS: Our results suggest that the intercellular communication between tumor cells and surrounding stroma cells can be altered by microenvironment which increased quantity of exosomes and diversity of miRNAs in this study. Imbalance of oncogenic and tumor suppressor miRNAs caused by cytostatic treatments may influence the antiproliferative and metastasis inhibitory effect of cytostatic agents.


Asunto(s)
Exosomas/metabolismo , Neoplasias Nasofaríngeas/metabolismo , Antibióticos Antineoplásicos/farmacología , Comunicación Celular , Línea Celular Tumoral , Citostáticos/farmacología , Doxorrubicina/farmacología , Exosomas/efectos de los fármacos , Humanos , MicroARNs/metabolismo , Neoplasias Nasofaríngeas/patología , Microambiente Tumoral
20.
Med Pr ; 67(4): 499-508, 2016.
Artículo en Polaco | MEDLINE | ID: mdl-27623830

RESUMEN

BACKGROUND: A growing number of cancer cases enhances the usage of cytostatic agents and thereby contributes to the increase in the number of health care workers occupationally exposed to cytostatics. MATERIAL AND METHODS: This article presents the results of the survey aimed at obtaining data on the reduction of occupational exposure through using personal protective equipment by the medical and pharmaceutical personnel involved in handling cytostatics. The questionnaires were sent by mail or e-mail to oncology hospitals and pharmacies preparing cytostatic drugs. Responses were received from 94 people employed in these workplaces. The main questions concerned the forms of cytostatics; job activities; types of personal protective equipment used and working time under exposure to cytotoxic drugs. RESULTS: The majority (over 90%) of the healthcare personnel declared the use of personal protective equipment when working under conditions of exposure to cytostatic drugs. Depending on the type of protection, 15-35% of people reported that the most frequent time of their single use of the apron, the overalls, the gloves, the cap, the goggles or the respirators did not exceed few minutes. Gloves were changed most frequently. However, half of the responses indicated that the time after which the respondents removed protection equipment greatly differed. CONCLUSIONS: Almost the whole group of respondents applied personal protective equipment when working under exposure to cytostatics. However, personal protective equipment was not used every time in case of exposure. The medical and pharmaceutical staff worked under exposure to cytostatics for a few or even dozen hours during the working day. Med Pr 2016;67(4):499-508.


Asunto(s)
Antineoplásicos/efectos adversos , Enfermedades Profesionales/inducido químicamente , Enfermedades Profesionales/prevención & control , Exposición Profesional/prevención & control , Administración de la Seguridad/métodos , Monitoreo del Ambiente/métodos , Humanos , Servicio de Oncología en Hospital
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA